Is "lying thin" a reality? Two weight loss pills have been submitted for application! Management | Weight | Weight loss pills
On August 21st, the official website of the Drug Evaluation Center of the National Medical Products Administration showed that the registration application of Lilly's tirzepatide injection for long-term weight management of overweight patients with adult obesity or at least one weight related comorbidities has been officially accepted. Telposide has also become another weight loss drug for weight management that has been applied for in China, following Novo Nordisk's Smegglutide. According to a real world study of 15.8 million people published in the journal diabetes, Obesity and Metabolism by Chen Kang, et al., Department of Endocrinology, First Medical Center, General Hospital of the Chinese People's Liberation Army on August 17, the proportion of overweight men in China exceeded 40%. Telposide is currently the world's first and only glucose dependent insulinotropic peptide and glucagon like peptide-1 dual target receptor agonist for long-term weight management in adult obese or overweight patients, administered once a week. In September 2022, Lilly submitted an application for blood glucose control registration of tilporide for the treatment of adult type 2 diabetes patients in China, which is also under review. In May 2022, Tilpoltide was approved by the US Food and Drug Administration to improve the blood sugar control of adult patients with type 2 diabetes, and has been approved in the EU, Japan, etc. In October 2022, the US FDA granted Telposide a fast track qualification for improving long-term weight management indications in overweight adults who are obese or have at least one comorbidities, in order to accelerate the approval of this indication. Lilly's later clinical trials have shown that while achieving blood sugar control goals, telposide can also help obese patients lose weight. The results of an international clinical trial for ordinary obese people without type 2 diabetes showed that the average weight of the subgroup receiving the highest dose of tilporide was reduced by 22.5%, and 63% of the subjects lost at least 20% of their weight, which was the first drug under study to reduce the average weight by more than 20% in the phase III clinical trial. In addition, the results of the registered clinical trial SURBOUNT-CN of Tilpodide for obesity or overweight in China will be announced at the academic annual meeting of the European diabetes Research Association in October this year, which included 210 Chinese patients. Lilly said that obesity will increase the risk of diabetes and a variety of metabolic diseases. Therefore, by treating obesity, the chance of metabolic diseases and related complications can be reduced, so as to improve people's health. Wall Street has also raised its sales forecast for telposide as a result. According to research firm Refinitiv, analysts currently estimate that telposide's sales will reach $4.7 billion in 2026. In China, the incidence of obesity and overweight is also becoming increasingly common. According to the above real world research on 15.8 million people in diabetes, Obesity and Metabolism magazine, according to the BMI classification standard of overweight and obesity in China, overweight people accounted for 34.8% of the subjects and obese people accounted for 14.1%; Among them, 41.1% are overweight males and 27.7% are overweight females; The proportion of obese males is 18.2%, while females account for 9.4%. The study also found that the most common complications of overweight/obese participants were fatty liver, pre diabetes, dyslipidemia and hypertension, and the number of complications increased with the increase of body mass index. Due to its optimistic outlook on the potential of China's obesity treatment market, Novo Nordisk also submitted a marketing application for the weekly injection of Smegglutide 2.4mg for long-term weight management in China in June this year, which was accepted by the National Medical Products Administration. Previously, the drug "Novotel" used by Smeaglutide for hypoglycemic indications has been listed in China and included in the